Endocrine Abstracts

Growth hormone deficiency (GHD) can occur after treatment for acromegaly. It is unclear whether treatment with recombinant human growth hormone (rhGH) in these patients is beneficial. Patients were randomized to either 1 year of rhGH replacement (n=10) or placebo followed by rhGH replacement for 1 year (delayed rhGH treatment, n=6). Sixteen patients (8 men, mean age 56 years) with GHD after treatment for acromegaly were studied. Study parameters were assessed at ...

Objective: To identify factors influencing the development of osteoarthritis during long-term control of acromegaly, focusing on disease specific parameters, growth hormone (GH) and insulin-like growth factor I (IGF-I) concentrations and duration of disease, adjusted for the well-known determinants of primary osteoarthritis.Design: Follow-up study.Methods: We studied 67 patients, with adequate biochemical control of acromegaly for ...

Objective: To evaluate the impact of the genomic deletion of exon 3 in the growth hormone receptor (d3GHR) on co-morbidities of acromegaly in a well-characterized cohort of patients with long-term remission of acromegaly.Design: Cross sectional study.Methods: The presence of the d3GHR polymorphism was assessed in 86 acromegalic patients and related to clinical outcome, i.e. anthropometric parameters, osteoarthritis, and the metabol...